As reviewed by Stiewe and Haran [16], cancer-associated mutations alter p53 in three ways: they promote the loss of wild-type (wt) p53 DNA binding, trigger dominant-negative inhibition of wtp53 by the mutant p53 in the monoallelic mutation setting, or induce the gain of new functions by mutant p53 through new protein–protein–DNA interactions. This evidence concerns the gene TP53 and cancer.